Caliway Reaches New Heights with MSCI Index Inclusion
Caliway Biopharmaceuticals (TWSE: 6919) has recently made significant waves in the international capital market by being added to the MSCI Global Standard Index. This prestigious inclusion is set to take effect shortly, reflecting Caliway's growing reputation on a global scale.
Understanding the Impact of MSCI Inclusion
The MSCI Global Standard Index serves as a crucial benchmark for equity markets around the world, guiding many institutional investors in their portfolio decisions. This elevation from the MSCI Global Small Cap Index to the Global Standard Index indicates Caliway's solid market capitalization and liquidity.
Financial Recognition and Investment Opportunities
This transition not only boosts Caliway's visibility but also enhances its attractiveness to larger investment funds. An increase in foreign investments is expected due to the index change, showcasing the company’s financial transparency and growth potential.
Caliway's Pioneering Drug CBL-514 Approved for Phase 3 Study
Simultaneously, Caliway has announced that its flagship product, CBL-514, has received approval from Health Canada for the Phase 3 SUPREME-01 study. This follows similar clearance from the U.S. FDA, allowing the multicenter trial to recruit participants across multiple locations.
Details of the SUPREME-01 Study
The SUPREME-01 study will take place at 29 clinical sites and is designed to assess the safety and efficacy of CBL-514 for reducing abdominal fat. Targeting 300 participants, the study will compare the effects of CBL-514 against a placebo to gather comprehensive data on its performance.
Innovative Approach of CBL-514 in Fat Reduction
CBL-514 is recognized as the world's first injectable lipolysis drug targeting subcutaneous fat without systemic side effects. This innovative candidate represents a breakthrough in the field of non-surgical fat reduction therapies.
Clinical Trials and Future Prospects
To date, CBL-514 has undergone several clinical trials, demonstrating its efficacy and safety. With successful results, Caliway is exploring multiple indications for this drug, including treatments for cellulite and weight management challenges, making it a versatile tool for various patient needs.
Understanding the African Fat Rating Scale (AFRS)
Part of the criteria for gauging the effectiveness of CBL-514 involves the use of the Abdominal Fat Rating Scale (AFRS). This five-grade rating tool, vital in clinical evaluations, has been developed in alignment with FDA guidelines to ensure the accuracy and reliability of treatment responses.
About Caliway Biopharmaceuticals
Caliway is committed to advancing its clinical-stage biopharmaceutical initiatives, aiming to lead in the innovative development of aesthetic medicine. As a publicly traded entity on the Taiwan Exchange, Caliway strives to pioneer new therapeutic solutions that enhance patient quality of life.
Frequently Asked Questions
What does it mean for Caliway to be included in the MSCI Global Standard Index?
This inclusion enhances Caliway's visibility and credibility, potentially attracting more investment from global funds.
What is the significance of the Phase 3 study for CBL-514?
The Phase 3 study is a critical step toward obtaining approval for CBL-514 as a treatment for fat reduction, demonstrating its safety and efficacy.
How many participants will be involved in the SUPREME-01 study?
The study aims to recruit 300 participants to evaluate the effects of CBL-514 compared to a placebo.
What is the Abdominal Fat Rating Scale (AFRS)?
AFRS is a validated rating scale used to assess abdominal fat reductions in studies, providing reliable results based on clinician and patient evaluations.
What are Caliway's future plans for CBL-514?
Caliway looks to explore additional indications for CBL-514, including weight management and cellulite treatment options.
